Key Highlights
- $300M Bain Capital Backing Launches New Biotech with BMS Immunology Assets
On July 28, Bristol Myers Squibb formed a new independent company with Bain Capital, funded by $300 million, to advance five investigational immunology drugs, including a late-stage lupus treatment and mid-stage psoriasis therapy. BMS retains nearly a 20% stake and expects royalties and milestone payments from the venture. - Strategic Focus to Reset the Immune System and Drive Next-Gen Treatment Development
The partnership allows BMS to concentrate its immunology R&D on therapies designed to recalibrate immune responses while the new company develops promising assets displaced from BMS’s core portfolio. - Leadership and Collaboration to Accelerate Market Potential
Daniel Lynch has been named executive chairman and interim CEO of the new company, with BMS Chief Research Officer Robert Plenge joining the board alongside Bain partners. Canada Pension Plan Investment Board also participated in funding. - BMS Stock Experiences Slight Decline Ahead of Q2 Earnings Report
On July 30, BMS shares closed down 1.88% at $46.86 amid moderate trading volume. The company is set to report Q2 earnings on July 31, with analysts projecting slightly lower revenue and EPS compared to prior year figures.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical leader focused on innovative medicines in oncology, immunology, cardiovascular disease, and fibrosis. The company leverages partnerships and technology to accelerate healthcare innovation and deliver transformative therapies worldwide.
About Bain Capital
Bain Capital, LP is a leading global private investment firm headquartered in Boston, Massachusetts, managing approximately $185 billion in assets as of 2025. Founded in 1984, the firm invests across private equity, venture capital, credit, public equity, life sciences, and real estate. Bain Capital partners with management teams worldwide to drive strategic transformation and long-term growth. Committed to integrity, innovation, and lasting impact, Bain fosters partnerships that unlock value and operational excellence across its portfolio.
By
